COMPANY

Aveta Biomics

HQ: Bedford, MA source · avetabiomics.com ↗ · New England

Location: Bedford, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Glioblastoma Multiforme Head and Neck Cancer Glioma Head and Neck (HNSCC) Oropharyngeal Oral Cavity Oral Cavity Carcinoma Oropharynx Squamous Cell Carcinoma Oral Cavity Squamous Cell Carcinoma Squamous Cell Carcinoma of Oral Cavity Squamous Cell Carcinoma of the Oropharynx Glioblastoma APG-157

4Trials (company is sponsor)

Timeline

2026-07 Trial start Phase 3: APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma source ↗
Dec 13, 2023 Trial start Phase 1/Phase 2: Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab source ↗
Apr 22, 2022 Trial start Phase 2: Safety and Efficacy of APG-157 in Head and Neck Cancer source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 2 · Safety and Efficacy of APG-157 in Head and Neck Cancer · NCT05312710
Dec 31, 2026 (ESTIMATED) · Phase 1/Phase 2 · Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab · NCT06011109
2031-12 (ESTIMATED) · Phase 3 · APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma · NCT07667296

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06011109	Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab	Phase 1/Phase 2	Active, not recruiting	Dec 13, 2023	Dec 31, 2026 (estimated)
NCT07667296	APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Not yet recruiting	2026-07	2031-12 (estimated)
NCT05312710	Safety and Efficacy of APG-157 in Head and Neck Cancer	Phase 2	Active, not recruiting	Apr 22, 2022	2026-12 (estimated)
NCT05551013	Treatment of Recurrent GBM With APG-157 Via Expanded Access	Not listed	No longer available	Not listed	Not listed